Bioequivalence and Bioavailability Forum 04:38 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Sample size for 4-period 4-sequence crossover BE study [Power / Sample Size]

posted by Bryony Simmons - UK, 2018-02-01 12:16  - Posting: # 18320
Views: 8,039

Hi,

I am in the process of conducting a sample size calculation for a crossover BE study. There are four-treatments (2xreference dosages & 2xtreatment dosages) & I plan to use the Williams' design as follows:

ABCD
BDAC
CADB
DCBA

The coefficient of variation from previous studies is 20% & I am assuming the true test reference ratio to be between 0.95 and 1.05. I want to demonstrate bioequivalence (0.80-1.25) at 90% power at the 5% level.

Using these figures, if it was a standard AB/BA crossover, I estimate that I would require 12 individuals to complete each arm - is this correct? I am unsure how this calculation is extended to fit the 4x4 design - do I simply randomise 12 more individuals to each of the remaining two sequences?

Further, if I planned to have just 1 treatment dose changing the design as follows:

ABC
BCA
CAB

Is it reasonable to randomise 12 individuals per sequence?

I really appreciate any help on this question.

Best wishes,
Bryony


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,154 posts in 4,080 threads, 1,308 registered users;
online 11 (0 registered, 11 guests [including 7 identified bots]).

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed